following a full submission
golimumab (Simponi®) is not recommended for use within NHS Scotland.
Indication under review: treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
In a study of adults with moderately to severely active ulcerative colitis who had inadequate response or intolerance to conventional therapy, a greater proportion of patients given golimumab induction therapy achieved a clinical response compared with placebo. In patients who had a clinical response to golimumab induction, golimumab maintenance treatment was associated with a greater clinical response rate over 54 weeks, compared with placebo.
The company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice195KB (PDF)
Medicine details
- Medicine name:
- golimumab (Simponi)
- SMC ID:
- 946/13
- Indication:
- for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
- Pharmaceutical company
- MSD
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 13 October 2014